Redeye revises its estimates following the Q1 2024 report, which came in above our expectations in terms of margins while sales were somewhat lower due to weaker performance in the SDD segment. We consider the rebound of recurring revenues, which increased by 11% sequentially, alongside the higher margins to be the highlight of the report.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/